# Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

> **NCT03992066** · PHASE1 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 46 (actual)

## Conditions studied

- Anemia Associated With Chronic Kidney Disease

## Interventions

- **DRUG:** Vadadustat
- **DRUG:** Darbepoetin alfa
- **DRUG:** Epoetin alfa

## Key facts

- **NCT ID:** NCT03992066
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-28
- **Primary completion:** 2020-05-05
- **Final completion:** 2020-07-15
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03992066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03992066, "Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03992066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*